Back

COVID-19 vaccination confers long-term cardioprotection against post-COVID cardiovascular disease: >5-year evidence from causal mediation and target trial emulation

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention (2) Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Binyam Tariku Seboka

Baker Heart and Diabetes Institute, Melbourne (Australia)

7 More presentations in this session

Presentation thumbnail
The influence of medication costs on secondary cardiovascular prevention decisions: two discrete choice experiments among patients and prescribers
Miss E. Wempe (NL)
Abstract Slides
Presentation thumbnail
Low molecular weight heparin for AMI with frailty: short-Term outcomes after early PCI
Professor K. Chen (Tianjin, CN)
Abstract Slides
Presentation thumbnail
The German lipoprotein apheresis registry - summary of the thirteenth annual report
Doctor A. Vogt (Munich, DE)
Abstract Slides
Presentation thumbnail
The newest pillar is the most fragile: SGLT2 inhibitors show the lowest 12-month ongoing use among guideline-directed CAD medications in a 15-country European survey
Mr L. Kieviet (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Prevalence and characteristics of low-dose acetylsalicylic acid intake in the German population: insights from the German National Cohort (NAKO)
Professor J. Neumann (Hamburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Secondary prevention (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Protective effects of COVID-19 vaccination on endothelial function of patients with COVID-19
29 August 2022
thumbnail
Congress Presentation
Cardiac impairment in long covid 1-year post SARS-CoV-2 infection
29 August 2022
thumbnail
Congress Presentation
Influenza infection as a trigger for cardiovascular events: outcomes and prevention
25 August 2023
thumbnail
Congress Presentation
mRNA vaccines for COVID-19 are safe and effective in patients with cardiac amyloidosis
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources